# Alendronate

## Binosto effervescent 70mg

| TAH Drug Code      | [OBIN](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBIN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of osteoporosis in postmenopausal women. Treatment to increase bone mass in men with osteoporosis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | 1 tablet once weekly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Esophageal abnormalities (eg, stricture or achalasia) that delay esophageal emptying. Hypersensitivity to alendronate or any component of the product. Hypocalcemia; resolve prior to beginning therapy. Inability to stand or sit upright for 30 minutes. Patients at increased risk of aspiration should not receive oral solution or effervescent tablets.                                                                                                                                                                                                                                            |
| Adverse Effects    | Common: Abdominal pain (2.1-6.6%), Constipation (0.3-3.1%), Diarrhea (0.6-3.1%), Flatulence (2.6-4.1%), Indigestion (1.7-3.6%), Vomiting (pediatric patients, 29.4%), Headache (2.6%), Fever (24%), Influenza-like illness Serious: Heart failure, Esophageal erosions, Esophageal perforation, Esophageal stricture, Esophagitis (1.5%), Gastric ulcer (up to 13.2%), Ulcerative pharyngitis, acute, Ulcer of duodenum, Ulcer of esophagus (1.5%), Hypersensitivity reaction, Arthralgia, Bone pain, Myalgia, Osteonecrosis caused by drug, External auditory canal, Osteonecrosis of jaw (0.017-0.03%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/alendronate-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

